Report: Ranbaxy to launch generic Lipitor at end of November
NEW YORK — Ranbaxy Labs will launch its generic version of the world’s top-selling drug as originally planned, according to published reports.
Citing Japan’s Nikkei daily, Reuters reported that Gurgaon, India-based Ranbaxy would launch a generic version of Pfizer’s cholesterol medication Lipitor (atorvastatin) at the end of November.
Though the November launch had long been anticipated, speculation arose that Ranbaxy would have to sell rights to the drug due to manufacturing problems in India that had led the Food and Drug Administration to ban imports of some of its products from there.
But with the launch back on track, a generic version of Lipitor will be a major prize for Ranbaxy. According to IMS Health, the branded version of the drug had U.S. sales of $7.2 billion last year. Under the Hatch-Waxman Act of 1984, as the first company to win approval of a generic version of Lipitor, Ranbaxy will have the exclusive right to market the generic for 180 days, in direct competition with Pfizer.
Still, the company is expected to face additional competition in the form of an authorized generic marketed by Watson Pharmaceuticals. An authorized generic is the branded drug sold under its generic name at a reduced price, usually through a third-party company, as a way of creating a third front of competition against the actual generic.
Robert Yates to lead Merck KGaA’s life science division
DARMSTADT, Germany — Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker’s life science division.
Yates will report to Bernd Reckmann, who leads the company’s chemicals business sector, which includes the Merck Millipore and performance materials division. Millipore was acquired by Merck in July 2010.
Prior to his new role, Yates worked at Roche for 22 years, most recently in Roche’s diagnostics division, where he led the life sciences business in Penzberg, Germany.
Bristol-Myers Squibb completes Amira acquisition
NEW YORK — Bristol-Myers Squibb has completed its previously announced acquisition of another drug maker.
Bristol said it has completed the acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals, based in San Diego, for $325 million. Amira’s portfolio focuses on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
The transaction was originally announced on July 21.